2 active not recruiting, 1 completed, 1 enrolling by invitation, 1 not yet recruiting. 6 Phase 2, 3 Phase 1, 1 Early Phase 1, 1 Phase 3.
Follow Eledon Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation Tegoprubart, Tacrolimus - Kidney Transplant Rejection | Phase 3 | Not yet recruiting | Eledon Pharmaceuticals | 620 | 2026-10-01 | 2026-09-30 |
| Tolerance Through Mixed Chimerism (Sip-Tego) Combined Kidney/Bone Marrow Transplant, Donation of Kidney / Bone Marrow, Conditioning Regimen (Rituxan, Siplizumab (or ATGAM), Cyclophosphamide, Tegoprubart) - Kidney Failure, Transplant Recipient (Kidney) | Early Phase 1 | Active not recruiting | Tatsuo Kawai, MD, PhD | 12 | 2025-05-31 | 2026-09-25 |
| Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D) Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy - Type 1 Diabetes Mellitus | Phase 1 / Phase 2 | Active not recruiting | University of Chicago | 70 | 2024-03-04 | 2026-09-22 |
| Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients AT-1501, Tacrolimus - Kidney Transplant Rejection | Phase 2 | Enrolling by invitation | Eledon Pharmaceuticals | 132 | 2023-10-25 | 2025-12-10 |
| Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation AT-1501, Tacrolimus - Kidney Transplant Rejection | Phase 2 | Completed | Eledon Pharmaceuticals | 127 | 2023-08-30 | 2026-07-22 |
| Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D AT-1501 IV Infusion, Isolated cadaveric islet cells - Brittle Type 1 Diabetes Mellitus | Phase 1 / Phase 2 | Withdrawn | Eledon Pharmaceuticals | 2022-09-30 | 2023-01-18 | |
| Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN) AT-1501 - IgA Nephropathy, IgAN | Phase 2 | Terminated | Eledon Pharmaceuticals | 24 | 2022-03-21 | 2024-03-26 |
| Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant AT-1501 - Prevention of Rejection in Kidney Transplant | Phase 1 / Phase 2 | Recruiting | Eledon Pharmaceuticals | 48 | 2022-02-18 | 2025-06-29 |
Kidney Failure, Chronic (4) · Diabetes Mellitus, Type 1 (2) · Autoimmune Diseases (1) · Diabetes Mellitus (1) · Endocrine System Diseases (1) · Glomerulonephritis, IGA (1) · Hyperglycemia (1) · Hypoglycemia (1) · Immune System Diseases (1) · Metabolic Diseases (1) · Proteinuria (1) · Renal Insufficiency (1)
Tacrolimus (3) · Antilymphocyte Serum (1) · Cyclophosphamide (1) · Islets of Langerhans Transplantation (1) · Rituximab (1) · Transplantation Conditioning (1) · siplizumab (1)
United States (6) · Australia (4) · Brazil (3) · Canada (3) · Spain (3) · United Kingdom (3) · France (2) · Germany (2) · Croatia (1) · Malaysia (1) · New Zealand (1) · Philippines (1) · Poland (1) · Sri Lanka (1) · Thailand (1)
Jeff Bornstein, MD (1) · Piotr Witkowski, MD PhD (1) · Tatsuo Kawai, MD PhD (1)
2023 (1)